Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Endocrinology
•
Diabetes
•
Primary Care
Can a patient with a PMHx of pancreatic injury or disease (i.e. blunt trauma, recurrent pancreatitis) take a GLP-1 agonist safely in the setting of morbid obesity and type 2 diabetes?
Related Questions
What is the optimal BP target for patients with diabetes and hypertension to reduce their risk of MI/stroke?
Do you recommend routinely monitoring pancreatic markers such as amylase and lipase while receiving GLP1 R agonist or dual agonist therapies to determine their risk of pancreatitis?
When do you recommend screening patients with T2DM for heart failure?
When and how should we be stopping GLP-1 Receptor Agonist/Dual Agonist therapy?
Is it safe to prescribe Invokana or Metformin for patients taking Biktarvy?
Do you recommend the use of Korlym (Mifepristone) for patients with difficult to control diabetes and evidence of mild endogenous hypercortisolism of unknown source?
When managing patients with suspected MASLD, what specific criteria or findings would prompt you to refer them to hepatology?
Which patients would benefit most from teplizumab therapy to delay the onset of T1DM?
Can rapid weight loss following GLP1 R agonist therapy lead to postprandial hypoglycemia and if so, what are the treatment options outside of dietary modifications?
How do you counsel patients on the use of compounded weight loss medications?
